Research highlight within Nature Reviews Rheumatology

Period7 Jan 2019

Media contributions


Media contributions

  • TitleCancer risk associated with anti-TIF1 antibodies
    Degree of recognitionInternational
    Media name/outletNature Reviews Rheumatology
    Media typePrint
    Country/TerritoryUnited Kingdom
    Descriptionatients with dermatomyositis are more likely to develop cancer if they are positive for anti-transcriptional intermediary factor 1 (TIF1) antibodies than if they are negative (HR 3.4 (95% CI 2.2–5.4)), according to the results of a UK study of 263 patients. During a 10-year follow-up period, cancer occurred exclusively within a 3-year window either side of diagnosis in anti-TIF1 antibody-positive patients and was most common in patients over the age of 39. Patients with anti-TIF1 antibodies also had a higher risk of ovarian cancer than those without (19% of cancers versus 2% of cancers, respectively; P < 0.05).
    Producer/AuthorJoanna Collison
    PersonsHector Chinoy, Alexander Oldroyd, Janine Lamb

Research Beacons, Institutes and Platforms

  • Lydia Becker Institute